Wolfhard Frost · Bessemerweg 13 · 33611 Bielefeld
E-Mail: info@prostata-sh.info

PSA Selbsthilfegruppe Prostatakrebs Bielefeld



im November 2007 zeigte eine Phase III Studie:

CONCLUSIONS. Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden.

Der PK-spezifische Überlebensvorteil war so gut wie nicht vorhanden.

In den Foren in den USA war zu lesen: About a decade ago, Abbott Laboratories started to investigate the potential of a selective endothelin receptor antagonist called atrasentan or Xinlay™ for the treatment of advanced forms of prostate cancer.

A randomized Phase II trial initially suggested that atrasentan might be an effective form of treatment for hormone-refractory disease, but two later, randomized, double-blind, placebo-controlled, Phase III clinical trials showed no efficacy of atrasentan monotherapy in the management of either metastatic, castration-resistant prostate cancer (mCRPC) or non-metastatic, castration-resistant disease.

Mehr dazu unter Atrasentan

Und an anderer Fundstelle im Internet ist zu Atrasentan und Xinlay lesen:
Trial and other data
Treatment of diabetic nephropathy and neuropathy

March 11: Phase II study results suggest that atrasentan used with a renin-angiotensin system may reduce albuminuria in pts with type 2 diabetes. Key findings from the 8-week study of three doses of atrasentan (0.25 mg, n=22; 0.75 mg, n=22; 1.75 mg, n=22) vs. placebo (n=23) were: Atrasentan significantly reduced urine albumin-to-creatinine (UACR) ratio in the 0.75 mg and 1.75 mg groups vs. placebo (P=0.001 and P=0.011, respectively). Reduction from baseline to final UACR was 21%, 42%, and 35% in the 0.25 mg, 0.75 mg and 1.75 mg groups vs. 11% in placebo (P=0.291, P=0.023 and P=0.073, respectively). A significantly larger proportion of subjects achieved >40% reduction in UACR from baseline in the 0.75 mg group vs. placebo (50% vs 17% respectively, P=0.029). Peripheral oedema was the most common adverse event (14%, 18% and 46% for 0.25, 0.75 and 1.75 mg with P=0.007 for 1.75 mg vs. 9% in placebo). Other adverse events that occurred in >5% of patients and at a rate >5% vs. placebo included dizziness, urinary tract infection, headache and hypoglycemia. Due to the small numbers of patients in each treatment group and the low event rates, the significance of these other adverse events is unknown.

Dezember 2011


Atrasentan, Xinlay